Anti-thrombotic drug candidate
Dr. Neil Hayward, co-founder, President, and CEO at eXIthera Pharmaceuticals, Inc., discusses the need for a new anti-thrombotic drug and how eXIthera is addressing that need with their lead product candidate EP-7041. The next step for EP-7041 is Phase 2 clinical trials on cardiac surgery patients.
Frequently Asked Questions
What is the main topic discussed in this episode of Health Professional Radio?
This episode covers important developments in healthcare, including updates on Surgery. Health Professional Radio brings you expert insights and analysis on the latest medical news affecting healthcare professionals and patients alike.
How can healthcare professionals benefit from this information?
Healthcare professionals can stay informed about the latest developments in Surgery and related fields, enabling them to provide better patient care. Staying current with medical news helps clinicians make evidence-based decisions in their practice.
Where can I find more information about Surgery?
For more detailed information, listen to the full episode on Health Professional Radio and visit hpr.fm for additional resources. You can also subscribe to our podcast for regular updates on healthcare news and expert interviews.
Dr. Neil J. Hayward, Ph.D. is the co-founder, President, and Chief Executive Officer at eXIthera Pharmaceuticals, Inc. He has over 30 years of experience in discovery and preclinical research and development. Dr. Hayward holds his B.Sc. from the University of London and his M.Phil. and Ph.D. in Pharmacology from the University of Cambridge, UK.
Medical Disclaimer
The information provided on this website is for general informational purposes only and is not intended as medical advice. Always consult with a qualified healthcare professional for medical advice, diagnosis, or treatment. Never disregard professional medical advice or delay in seeking it because of something you have read on this website.
